2mg / Vial HGH Human Growth Peptide CJC 1295 Without Dac CAS 863288-34-0

2mg / vial HGH Human Growth Peptide CJC 1295 Without Dac CAS 863288-34-0
Skype: clarasteroid

Quick detail :

Product name : CJC 1295 ; CJC 1295 without DAC
Alias: CJC-1295 Acetate; CJC1295(Without DAC)
CAS No.: 863288-34-0
Molecular Formula: C165H271N47O46
Molecular Weight: 3649.30
Purity (HPLC): 98.0%
Appearance: White powder
Single Impurity(HPLC): 1.0%
Amino Acid Composition: 10% of theoretical
Peptide Content(N%): 80%(by %N)
Water Content(Karl Fischer): 6.0%
Acetate Content(HPIC): 15.0%
MS(ESI): N/A
Mass Balance: 95.0~105.0%

CJC-1295:

CJC-1295, also known as DAC:GRF (short for drug affinity complex:growth hormon-releasing factor), is a synthetic analogue of growth hormon-releasing hormone (GHRH) (also known as growth hormon-releasing factor (GRF)) and a growth hormon secretagogue (GHS) . It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regards to half-life.

CJC-1295 markedly increases plasma growth hormon (GH) and insulin-like growthe factor 1 (I G F-1) levels in both animals and humans. With a single injection, in human subjects, CJC-1295 increases plasma GH levels by 2- to 10-fold for 6 days or longer and plasma IGF-1 levels by 1.5- to 3-fold for 9 to 11 days. The drug has an estimated half-life of about 6 to 8 days in humans. With multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days.

CJC-1295 has been shown to extend the half-life and bioavailability of growth-hormon-releasing hormon 1-29 and stimulate insulin-like growthe factor 1secretion. It increases the half-life of acting agents by bioconjugation.

CJC-1295 has found use for bodybuilding purposes.

As we know, CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a hormone releasing hormone (GHRH) analog.
Clinical Research was first conducted for CJC-1295 during the MID-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects
Another very positive benefit of CJC-1295 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS is decreased significantly in older adults and also with people who tend to exercise later in the evening. Clinical studies have shown that a once-daily administration of CJC-1295, a long-acting hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH can induce significantly deeper sleep in a mouse.
Various experiments have been conducted to test the effectiveness of CJC-1295. The Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased concentrations 1.5-3 fold for 9-11 days. The mean half life was 5.8-8.1 days and after multiple doses mean levels remained above baseline for up to 28 days following. No serious adverse reactions were reported in any group participating in this research study. This peptide has the ability to stimulate hormone very significantly.

Product Description:

Introduction:CJC-1295 is a synthetic GHRH analog that selectively and covalently binds to endogenous albumin after injection, thereby extending its half-life and duration of action. Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg / kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.

DAC or no DAC?

As I have just stated above, when a person sees the term CJC 1295 without DAC this is really means that they are looking at MOD GRF 1-29. This tetrasubstitued peptide is a modified version of the original GRF 1-29 peptide better known as Semorelin. Due to the extreme short half life of the original GRF 1-29, chemists were able to modify the peptide to offer a longer biological activity that reduced the metabolic clearance. Although with MOD GRF 1-29 its modification had resulted in a greater peptide bond, the average user will still likely need to inject two to three times a day with a GHRP to get the maximum effectiveness for releasing endogenous growth hormone.

Now when the drug affinity complex (DAC) was added to CJC 1295, it allowed for an even greater possibility to utilize smaller GH pulses (what was once thought of as a bleed) that, when combined with a GHRP, will activate growth hormone stores to release throughout the day and night. When the DAC component was added, this allowed the peptide half-life to be extended to about one week and also provided for steadier blood levels after injection. Now that we understand how important the DAC factor is, this becomes a much more viable and cost effective way to utilize CJC 1295 with DAC along with a GHRP. The DAC, when added, is able to bind to albumin that circulates the body, literally being able to last for days as it looks for receptors to bind to.

So, in short, if you prefer to use shorter spikes of GH release then the use of the MOD GRF 1-29 (CJC 1295 without DAC) is going to be optimal. However, if your prefer fewer injections and still want to unleash your growth hormone stores, then 2-3 times a week injections of CJC 1295 with DAC along with your daily injection of GHRP would be the way to proceed for maximizing growth hormone release.

We also hot selling for below items: